Why This Matters to Distributors: Cencora’s latest moves show how large distributors are seeking growth beyond traditional product distribution by investing in AI, specialty services, and deeper customer integration.
Cencora is sharpening its focus on specialty pharmaceuticals, artificial intelligence and physician practice management as the healthcare distributor continues to reposition itself around higher-growth services and technology-driven operations.
During its fiscal second-quarter earnings call, executives highlighted new investments in AI-powered tools, continued expansion of specialty pharmaceutical services and ongoing efforts to streamline the company’s portfolio around what CEO Robert Mauch described as a “pharmaceutical-centric strategy.”
The strategy reflects a broader shift underway in healthcare distribution as companies look beyond traditional product fulfillment to drive growth through specialty services, data, technology, and closer ties to patient care providers.
One of the company’s newest initiatives is the deployment of artificial intelligence tools within customer support operations. Cencora said the technology is helping improve service consistency, issue resolution and customer visibility across its network and will be expanded more broadly throughout the organization.
The company also reported on continued progress in specialty pharmaceuticals, an area that remains a central growth driver. Its global specialty logistics business posted a second consecutive quarter of operating income growth, supported by new contracts involving cell and gene therapies and laboratory logistics services. Executives say demand is increasing as pharmaceutical manufacturers bring more complex therapies to market that require specialized handling and distribution capabilities.
Cencora is also expanding its reach into healthcare delivery through physician practice management organizations. Following its acquisition of OneOncology in February, the company has begun integrating the oncology platform with its existing Retina Consultants of America network.
Executives said teams from both organizations are collaborating on physician recruitment, clinical research, back-office operations, and other shared services designed to improve performance across the platforms. The effort represents one of the company’s most significant strategic initiatives as it seeks to build scale in specialty care settings.
At the same time, Cencora is narrowing its business focus. During the quarter, the company agreed to merge MWI Animal Health with Covetrus and completed the sale of its U.S. hub consulting services business. Management said the moves are intended to concentrate resources on pharmaceutical distribution, specialty healthcare services, and physician practice operations.
The strategic changes come as traditional pharmaceutical distribution faces increasing pressure from drug pricing changes, biosimilar conversions and evolving customer purchasing patterns. Cencora executives said the company remains focused on growing operating income through specialty services, logistics capabilities, and technology investments rather than relying solely on distribution volume growth.
For distributors, the message is becoming increasingly clear: future growth is likely to come from specialized services, digital capabilities, and deeper customer relationships rather than product distribution alone. Cencora’s latest initiatives provide one of the clearest examples yet of how that transition is unfolding among the industry’s largest players.
Cencora reported fiscal second-quarter revenue of $78.4 billion, up 4% from the prior-year period, while adjusted diluted earnings per share increased 7.5% to $4.75. Operating income rose 6% to approximately $1.3 billion. The company’s U.S. Healthcare Solutions segment generated revenue of $68.8 billion, up 3%, while International Healthcare Solutions revenue increased 13% to $7.6 billion.
For the first six months of fiscal 2026, Cencora generated approximately $155 billion in revenue. The company raised its full-year adjusted earnings guidance to $17.65 to $17.90 per share and increased its operating income growth forecast to 12% to 14%, while lowering expected revenue growth to 4% to 6% from a previous range of 7% to 9%.
Do not miss any content from Distribution Strategy Group. Join our list.
Share this article:
